Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.

MLA

Rensburg, Walter, et al. “Tirofiban versus Abciximab: Tirofiban Is Administered at Suboptimal Dosages When Evaluated in an Arterial Thrombosis Model in Non-Human Primates.” Clinical & Experimental Medicine, vol. 12, no. 4, Dec. 2012, pp. 257–63. EBSCOhost, https://doi.org/10.1007/s10238-011-0171-4.

APA

Rensburg, W., Roodt, J., Lamprecht, S., Meiring, S., & Badenhorst, P. (2012). Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates. Clinical & Experimental Medicine, 12(4), 257–263. https://doi.org/10.1007/s10238-011-0171-4

Chicago

Rensburg, Walter, Jan Roodt, Seb Lamprecht, S. Meiring, and Philip Badenhorst. 2012. “Tirofiban versus Abciximab: Tirofiban Is Administered at Suboptimal Dosages When Evaluated in an Arterial Thrombosis Model in Non-Human Primates.” Clinical & Experimental Medicine 12 (4): 257–63. doi:10.1007/s10238-011-0171-4.